News AACR 2025: Quintet of investigational oncological drugs puts... Ascentage Pharma, specialising in haematological malignancies, has presented results from five preclinical studies at AACR 2025.
Oncology Driving innovation in multiple myeloma to improve the patien... Despite being the second most common haematologic cancer globally, treatment options for multiple myeloma remain limited, with a significant need for new therapies.1
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.